Drug Profile
Research programme: antibacterials - Meiji Seika Kaisha
Alternative Names: CP-5484; CPZ-A; CPZ-B; CPZ-C; CPZ-D; CPZ-E; CPZ-F; CPZ-G; TS 2037Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Meiji Seika Kaisha
- Developer Meiji Seika Pharma
- Class Aminoglycosides; Carbapenems; Macrolides; Nucleosides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
- Discontinued Tuberculosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Japan
- 24 Jul 2008 Preclinical development is ongoing
- 15 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Viral Infections Antimicrobial Activity section